Switch theme
Sign up to access all valuation multiples
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
2012
88
LTM Revenue n/a
LTM EBITDA n/a
$37.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Molecure has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Molecure achieved revenue of n/a and an EBITDA of -$7.1M.
Molecure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Molecure valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0K | n/a | XXX | XXX | XXX |
| Gross Profit | -$0.4M | -$0.4M | XXX | XXX | XXX |
| Gross Margin | -1634566% | -Infinity% | XXX | XXX | XXX |
| EBITDA | -$4.2M | -$7.1M | XXX | XXX | XXX |
| EBITDA Margin | -16413896% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$3.9M | -$4.7M | XXX | XXX | XXX |
| Net Margin | -15263697% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Molecure's stock price is PLN 8 (or $2).
Molecure has current market cap of PLN 158M (or $40.5M), and EV of PLN 147M (or $37.7M).
See Molecure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37.7M | $40.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Molecure has market cap of $40.5M and EV of $37.7M.
Molecure's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Molecure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Molecure and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $37.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -5.3x | XXX | XXX | XXX |
| P/E | -5.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMolecure's NTM/LTM revenue growth is n/a
Molecure's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Molecure's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Molecure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Molecure and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 67% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Molecure acquired XXX companies to date.
Last acquisition by Molecure was XXXXXXXX, XXXXX XXXXX XXXXXX . Molecure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Molecure founded? | Molecure was founded in 2012. |
| Where is Molecure headquartered? | Molecure is headquartered in Poland. |
| How many employees does Molecure have? | As of today, Molecure has 88 employees. |
| Is Molecure publicy listed? | Yes, Molecure is a public company listed on WAR. |
| What is the stock symbol of Molecure? | Molecure trades under MOC ticker. |
| When did Molecure go public? | Molecure went public in 2018. |
| Who are competitors of Molecure? | Similar companies to Molecure include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Molecure? | Molecure's current market cap is $40.5M |
| Is Molecure profitable? | Yes, Molecure is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
